Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRC EBOADC069 00 VP

Drug Profile

VRC EBOADC069 00 VP

Alternative Names: Bivalent Ebola adenoviral vector vaccine - NIAID/Okairos AG; Bivalent Ebola adenoviral vector vaccine - Okairos AG/NIAID; Bivalent Ebola vaccine - NIAID/Okairos AG; Bivalent Ebola vaccine - Okairos AG/NIAID; Bivalent Ebola virus vaccine - NIAID/Okairos AG; Bivalent Ebola virus vaccine - Okairos AG/NIAID; cAd3 EBO - NIAID/Okairos AG; cAd3-EBO - Okairos AG/NIAID; cAd3-EBO-S; chAd-EBOV - NIAID/Okairos AG; ChAd3-SUDV; Ebola sudan virus vaccine - Sabin; VRC-EBOADC069-00-VP

Latest Information Update: 16 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; ReiThera
  • Developer National Institute of Allergy and Infectious Diseases; Sabin Vaccine Institute; University of Maryland, Baltimore
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 13 Jan 2023 VRC EBOADC069 00 V is still in phase-I development in Ebola-virus-infections (Prevention) in Mali, Uganda and USA (IM, Injection)
  • 13 Jan 2023 Sabin Vaccine Institute receives grant under a development contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of VRC EBOADC069 00 VP and VRC MARADC087 00 VP
  • 13 Jan 2023 Pooled efficacy data from preclinical and clinical trials in Ebola virus infections released by Sabin Vaccine Institute
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top